Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is for patients with locally advanced pancreatic cancer (cancer that involves the
local blood vessels so it cannot be removed without cutting major blood vessels) that cannot
be treated with surgery. The purpose of this study is to assess the safety and benefit of 6
three week cycles of chemotherapy treatment consisting of gemcitabine, capecitabine and
docetaxel (also called 'GTX'). The patients fall into two groups. Group I are those with only
venous involvement. Group II patients have arterial involvement and may also have venous
involvement. If there is arterial involvement, GTX will be followed by 5 and 1/2 weeks of
radiation therapy with gemcitabine and capecitabine. After the chemotherapy and radiation
treatment, participants may be able to have surgery to remove any remaining pancreatic
cancer.